Apogee Therapeutics Raises $403M via 5.75 Million Share Offering at $70
Apogee Therapeutics completed an underwritten offering of 5.75 million common shares, including a full exercise of a 0.75 million-share option, at $70 per share for approximately $403 million in gross proceeds. The financing bolsters its balance sheet to advance late-stage biologics programs targeting atopic dermatitis, asthma and eosinophilic esophagitis.
1. Public Offering Completion
Apogee closed its underwritten public offering of 5.75 million common shares, including full exercise of a 0.75 million-share overallotment at $70 per share, generating approximately $403 million in gross proceeds before fees and expenses.
2. Financial Impact and Runway
The transaction strengthens Apogee’s cash position, supporting ongoing clinical trials and extending its operating runway to deliver key data readouts and regulatory filings without near-term funding concerns.
3. Pipeline Advancement
Proceeds will underwrite development of its antibody portfolio—including APG777 in atopic dermatitis, asthma and eosinophilic esophagitis—and support preclinical programs targeting COPD and other inflammatory and immunology indications.